Stock listing
HKEX:6996 Antengene Corporation Limited (德琪醫藥) 股價
Home listing (HKEX) of Antengene Corporation Limited
Follow Antengene Corporation Limited into a list and get an email when it puts out news.
Share price · HKEX:6996
$2.35 HKD -0.17 (-6.7%)
Close on Nov 20, 2026
- Day range
- $2.29 – $2.62 HKDNov 20, 2026
- Volume
- 1.23M sharesNov 20, 2026
- Market cap
- $1.43B HKDAt the close on Nov 20, 2026 · price × 610.6M shares outstanding
- 52-week range
- $2.29 – $6.28 HKDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $3.21M HKDMedian day 870,550 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| HKEX:6996 · Home | $2.35 HKD | -0.17 (-6.7%) | 1,232,000 | $2.62 | $2.62 | $2.29 | $2.52 | Close on Nov 20, 2026 |
| Frankfurt:722 | €0.248 EUR | -0.022 (-8.1%) | — | €0.248 | €0.248 | €0.248 | €0.270 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · HKEX:6996 · HKD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.35 | -0.17 | -6.7% | $2.62 | $2.62 | $2.29 | 1,232,000 | |
| $2.52 | -0.01 | -0.4% | $2.615 | $2.615 | $2.37 | 2,963,500 | |
| $2.53 | -0.065 | -2.5% | $2.585 | $2.585 | $2.465 | 654,500 | |
| $2.595 | -0.115 | -4.2% | $2.90 | $2.90 | $2.525 | 980,500 | |
| $2.71 | -0.11 | -3.9% | $2.95 | $2.95 | $2.645 | 503,500 | |
| $2.82 | 0.00 | 0.0% | $2.955 | $2.955 | $2.76 | 626,000 | |
| $2.82 | 0.00 | 0.0% | $2.945 | $2.945 | $2.70 | 374,500 | |
| $2.82 | +0.125 | +4.6% | $2.905 | $2.905 | $2.76 | 391,500 | |
| $2.695 | -0.125 | -4.4% | $2.80 | $2.88 | $2.68 | 382,000 | |
| $2.82 | -0.13 | -4.4% | $2.89 | $2.89 | $2.725 | 332,000 | |
| $2.95 | +0.14 | +5.0% | $2.95 | $2.985 | $2.90 | 566,500 | |
| $2.81 | +0.14 | +5.2% | $2.67 | $2.85 | $2.655 | 1,249,751 | |
| $2.67 | -0.16 | -5.7% | $2.79 | $2.795 | $2.62 | 1,050,000 | |
| $2.83 | +0.04 | +1.4% | $2.95 | $2.95 | $2.775 | 221,000 | |
| $2.79 | -0.035 | -1.2% | $2.99 | $2.99 | $2.775 | 392,000 | |
| $2.825 | -0.015 | -0.5% | $2.90 | $2.90 | $2.735 | 282,000 | |
| $2.84 | +0.065 | +2.3% | $2.705 | $2.89 | $2.705 | 1,049,500 | |
| $2.775 | -0.165 | -5.6% | $3.025 | $3.025 | $2.735 | 1,096,500 | |
| $2.94 | +0.055 | +1.9% | $2.98 | $2.98 | $2.84 | 338,000 | |
| $2.885 | +0.045 | +1.6% | $3.00 | $3.00 | $2.73 | 829,000 | |
| $2.84 | -0.175 | -5.8% | $3.09 | $3.09 | $2.815 | 1,823,191 | |
| $3.015 | -0.05 | -1.6% | $3.08 | $3.10 | $2.97 | 1,426,500 | |
| $3.065 | -0.015 | -0.5% | $3.08 | $3.115 | $2.95 | 948,000 | |
| $3.08 | +0.11 | +3.7% | $3.10 | $3.165 | $3.00 | 704,500 | |
| $2.97 | 0.00 | 0.0% | $3.00 | $3.12 | $2.905 | 730,000 | |
| $2.97 | +0.035 | +1.2% | $3.06 | $3.06 | $2.90 | 858,100 | |
| $2.935 | -0.12 | -3.9% | $3.13 | $3.13 | $2.88 | 805,500 | |
| $3.055 | -0.135 | -4.2% | $3.225 | $3.225 | $3.045 | 883,000 | |
| $3.19 | -0.12 | -3.6% | $3.35 | $3.35 | $3.065 | 1,539,500 | |
| $3.31 | -0.19 | -5.4% | $3.50 | $3.50 | $3.27 | 980,500 | |
| $3.50 | -0.03 | -0.8% | $3.53 | $3.53 | $3.365 | 392,500 | |
| $3.53 | +0.14 | +4.1% | $3.40 | $3.54 | $3.365 | 378,000 | |
| $3.39 | +0.065 | +2.0% | $3.50 | $3.50 | $3.25 | 425,500 | |
| $3.325 | -0.135 | -3.9% | $3.405 | $3.405 | $3.20 | 742,500 | |
| $3.46 | +0.06 | +1.8% | $3.40 | $3.535 | $3.40 | 632,500 | |
| $3.40 | +0.04 | +1.2% | $3.56 | $3.56 | $3.32 | 578,000 | |
| $3.36 | -0.11 | -3.2% | $3.555 | $3.555 | $3.34 | 741,500 | |
| $3.47 | -0.005 | -0.1% | $3.475 | $3.575 | $3.34 | 505,500 | |
| $3.475 | -0.105 | -2.9% | $3.58 | $3.58 | $3.40 | 944,500 | |
| $3.58 | +0.04 | +1.1% | $3.66 | $3.66 | $3.555 | 1,442,000 | |
| $3.54 | -0.045 | -1.3% | $3.585 | $3.665 | $3.50 | 1,161,500 | |
| $3.585 | +0.275 | +8.3% | $3.31 | $3.645 | $3.30 | 1,231,000 | |
| $3.31 | +0.06 | +1.8% | $3.50 | $3.50 | $3.295 | 948,000 | |
| $3.25 | -0.03 | -0.9% | $3.28 | $3.345 | $3.185 | 1,729,500 | |
| $3.28 | -0.07 | -2.1% | $3.575 | $3.575 | $3.26 | 764,500 | |
| $3.35 | -0.075 | -2.2% | $3.27 | $3.57 | $3.265 | 530,500 | |
| $3.425 | +0.085 | +2.5% | $3.20 | $3.48 | $3.20 | 698,500 | |
| $3.34 | -0.11 | -3.2% | $3.50 | $3.50 | $3.16 | 1,492,500 | |
| $3.45 | 0.00 | 0.0% | $3.53 | $3.53 | $3.33 | 722,000 | |
| $3.45 | -0.05 | -1.4% | $3.555 | $3.555 | $3.42 | 510,000 | |
| $3.50 | 0.00 | 0.0% | $3.66 | $3.66 | $3.39 | 551,150 | |
| $3.50 | -0.055 | -1.5% | $3.695 | $3.695 | $3.415 | 1,420,500 | |
| $3.555 | -0.025 | -0.7% | $3.77 | $3.77 | $3.525 | 1,051,500 | |
| $3.58 | +0.02 | +0.6% | $3.77 | $3.77 | $3.545 | 679,000 | |
| $3.56 | +0.01 | +0.3% | $3.81 | $3.81 | $3.45 | 1,007,500 | |
| $3.55 | -0.125 | -3.4% | $3.83 | $3.83 | $3.525 | 1,072,500 | |
| $3.675 | -0.185 | -4.8% | $3.99 | $3.99 | $3.61 | 2,203,500 | |
| $3.86 | -0.185 | -4.6% | $4.00 | $4.03 | $3.805 | 1,763,000 | |
| $4.045 | +0.01 | +0.2% | $4.095 | $4.195 | $3.98 | 1,175,000 | |
| $4.035 | +0.055 | +1.4% | $4.075 | $4.19 | $3.99 | 1,435,000 | |
| $3.98 | +0.09 | +2.3% | $4.05 | $4.12 | $3.90 | 1,959,500 | |
| $3.89 | -0.015 | -0.4% | $4.075 | $4.185 | $3.85 | 1,340,000 | |
| $3.905 | -0.115 | -2.9% | $3.935 | $4.02 | $3.75 | 1,776,166 | |
| $4.02 | +0.27 | +7.2% | $3.87 | $4.125 | $3.84 | 2,090,893 |
- Ticker
- HKEX:6996
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- HKEX
- Currency
- HKD
What changed lately
Latest news release · Nov 20, 2026
Next Day Disclosure Return
Latest news
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Nov 4, 2026
Closed $2.95 (+5.0%) on Nov 5, 2026
Antengene Corporation Limited on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 62 in the last 12 months · 76 in all · newest Nov 20, 2026 · oldest 2025
- Decks
- 2 decks · latest November 2022
Where Antengene Corporation Limited is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| HKEX:6996 德琪醫藥 · Home listing · This page | HKEX | Hong Kong | HKD |
| Frankfurt:722 | Frankfurt | Germany | EUR |
| LS Exchange:A2QHCZ | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2QHCZ | Lang & Schwarz | Germany | EUR |
| Stuttgart:722 | Stuttgart | Germany | EUR |
| Tradegate:722 | Tradegate | Germany | EUR |
Valuation
EV/sales 6.8× against a median of 59.4×: the lowest of 7 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $838.4M HKD
- P/E
- Loss
- EV/sales
- 6.8×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.3×
- Gross margin
- 82.4%
- Operating margin
- −226.8%
- Net margin
- −227.0%
- Debt to equity
- 0.3×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Antengene Corporation Limited · HKEX:6996 | US$183.1M | US$107.0M | n/a | 6.8× | n/a | 1.3× | −227.0% | 0.3× | n/a |
| Cartesian Therapeutics, Inc. · NASDAQ:RNAC | US$187.3M | US$114.5M | n/a | 112× | n/a | n/a | n/a | n/a | 1.23 |
| Artiva Biotherapeutics, Inc. · NASDAQ:ARTV | US$186.9M | −US$123.1M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 1.34 |
| Inhibikase Therapeutics, Inc. · NASDAQ:IKT | US$185.2M | −US$8.17M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | 1.50 |
| Inventage Lab, Inc. · KRX:389470 | US$184.8M | US$112.6M | n/a | 61.3× | n/a | 2.8× | −127.0% | 0.2× | n/a |
| Whitehawk Therapeutics, Inc. · NASDAQ:WHWK | US$181.2M | US$11.70M | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 1.35 |
| Sol-Gel Technologies Ltd. · NASDAQ:SLGL | US$180.6M | US$137.0M | n/a | 95.4× | n/a | 4.2× | n/a | 0.0× | 0.67 |
| Tanvex BioPharma, Inc. · TWSE:6541 | US$180.5M | US$225.8M | n/a | 11.3× | n/a | 1.2× | −222.8% | 0.4× | n/a |
| Korro Bio, Inc. · NASDAQ:KRRO | US$179.4M | US$74.36M | n/a | 57.6× | n/a | 2.0× | n/a | 0.0× | 1.46 |
| Vogenx Inc · NASDAQ:VOGX | US$176.3M | US$94.21M | n/a | n/a | n/a | 2.1× | n/a | 0.0× | n/a |
| Nanexa AB · OMXSTO:NANEXA | US$175.6M | US$170.5M | n/a | 51.4× | n/a | 13.5× | −72.5% | 0.0× | n/a |
| Median of the others | US$180.9M | US$103.4M | 59.4× | 2.0× | −127.0% | 0.0× | 1.35 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.88 HKD · Analysts' mean
- EPS, year to Dec 2026
- 0.53 · 1 analyst
- Revenue, year to Dec 2026
- 830.3M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Jay Mei | Executive Director, Chairman of the Board, Chief Executive Officer |
| Peter Qian | PR / IR Contacts |
| Bing Hou | Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Aug 21, 2025 · Before open | +1.3% |
| Quarter to Mar 31, 2025 | Jun 13, 2025 · Before open | −9.3% |
| Q4 2024 | Mar 21, 2025 | +11.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2022) | Investor deck | 42 slides | November 2022 |
| Investor Presentation (November 2021) | Investor deck | 32 slides | Nov 29, 2021 |
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 105.3M | 92.0M | 67.3M | 160.1M | 28.8M | 0 | 11.0M | 6.80M |
| Cost of revenue | 18.5M | 17.8M | 12.3M | 28.1M | 4.58M | 0 | ||
| Gross profit | 86.8M | 74.2M | 55.0M | 132.0M | 24.2M | 0 | 11.0M | 6.80M |
| Research and development | 169.1M | 258.9M | 405.7M | 488.5M | 405.0M | 347.7M | 115.8M | 115.8M |
| Selling, general and administrative | 87.5M | 106.3M | 148.1M | 167.1M | 169.5M | 154.2M | 39.3M | 12.8M |
| Operating income | -238.9M | -364.7M | -691.5M | -878.9M | -618.2M | -502.3M | -144.1M | -134.8M |
| Depreciation and amortization | 23.9M | 26.9M | 30.0M | 27.2M | 11.5M | 4.09M | 1.51M | 763.0K |
| EBITDA | -215.0M | -337.8M | -661.5M | -851.7M | -606.7M | -498.2M | -142.6M | -134.0M |
| Interest expense | 2.30M | 642.0K | 898.0K | 974.0K | 698.0K | 1.03M | 836.0K | 11.2M |
| Income before tax | -239.1M | -319.3M | -581.2M | -601.5M | -655.5M | -2.93B | -323.8M | -146.0M |
| Income tax | 12.6M | 3.69M | ||||||
| Net income | -239.1M | -319.3M | -581.2M | -601.5M | -655.5M | -2.93B | -323.8M | -146.0M |
| Earnings per share, basic | -0.38 | -0.51 | -0.94 | -0.97 | -1.05 | -11.66 | -0.48 | -0.22 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 734.2M | 900.1M | 1.19B | 1.79B | 2.27B | 3.11B | 290.8M | 49.3M |
| Short-term investments | 107.0K | 106.0K | 4.90M | 3.43M | 2.33M | 1.70M | 453.4M | |
| Receivables | 27.5M | 18.7M | 9.68M | 29.8M | 7.01M | 17.5M | 8.35M | 11.4M |
| Inventory | 7.53M | 13.2M | 15.3M | 9.89M | 2.58M | 0 | ||
| Current assets | 783.5M | 956.2M | 1.24B | 1.90B | 2.41B | 3.13B | 755.6M | 77.1M |
| Property, plant and equipment | 57.7M | 229.4M | 86.1M | 66.1M | 4.09M | 3.28M | ||
| Total assets | 1.26B | 1.34B | 1.62B | 2.14B | 2.56B | 3.19B | 759.8M | 80.4M |
| Accounts payable | 7.99M | 3.58M | 3.86M | 7.82M | 1.48M | 16.5M | ||
| Current liabilities | 264.1M | 146.3M | 190.9M | 381.8M | 159.4M | 150.6M | 44.9M | 68.7M |
| Long-term debt | 191.0M | 220.0M | 180.0M | 30.0M | 0 | 0 | 1.27B | 138.1M |
| Total debt | 257.5M | 249.4M | 201.0M | 58.0M | 14.8M | 10.9M | 1.73B | 154.0M |
| Total liabilities | 614.9M | 493.9M | 471.2M | 428.8M | 163.3M | 156.6M | 1.32B | 239.0M |
| Shareholders' equity | 642.7M | 850.8M | 1.15B | 1.71B | 2.39B | 3.04B | -557.6M | -158.6M |
| Shares outstanding | 626.4M | 620.4M | 615.4M | 617.8M | 625.0M | 251.1M | 668.2M | 668.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -127.5M | -322.0M | -665.8M | -572.2M | -557.6M | -307.1M | -121.5M | -113.1M |
| Capital spending | -51.4M | -60.6M | -113.1M | -93.4M | -23.4M | -51.7M | -11.0K | -450.0K |
| Free cash flow | -178.9M | -382.6M | -778.9M | -665.6M | -581.0M | -358.9M | -121.5M | -113.6M |
| Cash from investing | 116.2M | 345.2M | 587.1M | -208.2M | -103.9M | -600.6M | -430.4M | 96.8M |
| Cash from financing | -3.19M | 45.2M | 131.8M | -20.7M | -81.3M | 2.79B | 771.8M | 31.6M |
| Share buybacks | -1.39M | 0 | 0 | -33.8M | -47.9M | -139.6M | 806.0M | 0 |
| Change in cash | -15.4M | 69.7M | 56.6M | -708.4M | -780.1M | 1.80B | 241.5M | 19.0M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Next Day Disclosure Return | Nov 20, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Nov 19, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Nov 18, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Nov 17, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Nov 16, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Nov 13, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Nov 12, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Nov 11, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Nov 10, 2026 | Next day disclosure return | HKEX |
| Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026 | Nov 4, 2026 | Monthly return | HKEX |
All 37 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Next Day Disclosure Return | Nov 3, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Nov 2, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Oct 30, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Oct 29, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Oct 28, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Oct 27, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Oct 26, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Oct 23, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Oct 22, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Oct 21, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Oct 20, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Oct 16, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Oct 15, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Oct 14, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Oct 13, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Oct 12, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Oct 9, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Oct 8, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Oct 7, 2026 | Next day disclosure return | HKEX |
| Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026 | Oct 7, 2026 | Monthly return | HKEX |
| Next Day Disclosure Return | Oct 6, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Oct 5, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Oct 2, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Sep 30, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Sep 29, 2026 | Next day disclosure return | HKEX |
| 2026 INTERIM REPORT | Sep 29, 2026 | Interim report | HKEX |
| Next Day Disclosure Return | Sep 28, 2026 | Next day disclosure return | HKEX |
Cap table
Built by 6ix from Antengene Corporation Limited’s releases
- Common shares
- 610,632,300
- Fully diluted
- 610,632,300
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 610,632,300 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 610,632,300 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Bing Hou | Executive Director · Since May 20, 2026 |
| Jay Mei | Executive Director, Chairman of the Board, Chief Executive Officer · Since at least Aug 24, 2026 |
| Jing Qian | Independent non-executive Director · Since at least Nov 5, 2026 |
| Peter Qian | PR / IR Contacts · Since at least Oct 3, 2026 |
| Rafael Fonseca | Independent non-executive Director · Since at least Nov 5, 2026 |
| Robert Gale | Independent non-executive Director · Since at least Nov 5, 2026 |
| Sheng Tang | Independent non-executive Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Antengene Corporation Limited.